Biovica is a Swedish biotech company that specializes in developing and commercializing innovative blood-based biomarker assays. Founded in 2009, our mission is to improve the monitoring and prediction of the efficacy of cancer therapies, with a primary focus on breast cancer. With breast cancer accounting for over 685,000 deaths annually, we work in collaboration with leading cancer institutes, collaborative groups, and pharmaceutical companies to develop products that can enhance outcomes and reduce costs.

One of our notable products is DiviTum, a biomarker test that measures cell proliferation, allowing for accurate monitoring and prediction of treatment efficacy. DiviTum has received CE labeling in Europe and FDA 510(k) clearance in the United States. Our dedication to collaboration, innovation, and ethical practices sets us apart in the field of cancer care.

Join us in our quest to transform the management of cancer through groundbreaking biomarker-based tests